Search Clinical Trials in the European Union

Duration
Visits
Phase
Oral
Benefits
Drugs
Locations
Clinical Specialty
961-980 of 1,694 trials

Futibatinib Safety Study for Cancer Patients

We are collecting long-term safety information for patients who previously benefited from futibatinib treatment. This study helps ensure that continuing the medication remains safe for them.

Malignant Solid Tumors1-2 yearsEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Ependymoma Treatment: SIOP Ependymoma II Program

We are exploring new chemotherapy options and surgical techniques for children and young adults with ependymoma. Our goal is to improve survival rates and treatment effectiveness compared to standard methods.

Ependymoma>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboInvestigational MedicinesOncologyPediatrics

Glibenclamide for High Blood Sugar in Premature Infants

We are studying whether an oral suspension of glibenclamide can help control high blood sugar in premature infants under 1500 grams. The trial will also look at its safety and effects on growth.

Neonatal Hyperglycemia>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesEndocrinologyPediatrics

Advanced Solid Tumors: ORIC-114 Study

We are testing a new drug, ORIC-114, for patients with advanced solid tumors that have EGFR or HER2 alterations. The study will assess its safety and effectiveness alone and with chemotherapy.

Solid Tumors3-6 monthsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesOncology

Multiple Myeloma: SABLe Study with Selinexor

We are investigating a new treatment combination for patients with newly diagnosed multiple myeloma who cannot have a transplant. The study aims to evaluate how well the treatment works and its effects on quality of life.

Multiple Myeloma>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteHematologyOncology

Triple Negative Breast Cancer: Sacituzumab Govitecan and Pembrolizumab Study

We are testing a new treatment combination for patients with triple negative breast cancer who have residual disease after surgery. The study aims to see if this combination improves survival compared to standard treatment options.

Triple Negative Breast Cancer3-6 monthsConfirmation phase (III)16-20 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

Multiple Sclerosis: Siponimod Therapy Study

We are exploring how siponimod affects inflammation in patients with active secondary progressive multiple sclerosis. The study aims to understand its impact on disease progression and patient health over time.

Progressive Multiple Sclerosis>2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesNeurology

Advanced Lung Cancer: Amivantamab and Lazertinib Study

We are exploring a new treatment combination for people with advanced non-small cell lung cancer who have an EGFR mutation and have not responded to earlier therapies. The goal is to see if this combination can improve treatment outcomes and safety.

Advanced Non-Small Cell Lung Cancer (NSCLC)1-2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesPartially RemoteOncologyPulmonology

Chronic Low Back Pain: Tricortin 1000 Study

We are testing Tricortin 1000 to see if it helps relieve pain better than a placebo and an existing treatment for chronic low back pain. This study aims to improve pain management for those experiencing acute flare-ups.

Low Back Pain≤3 monthsMonitoring phase (IV)≤5 visitsInvestigational MedicinesInternal MedicineOrthopedics and Traumatology

Major Depressive Disorder: Liposom Forte with Citalopram

We are studying whether Liposom Forte can enhance and speed up the response to citalopram in elderly patients with Major Depressive Disorder. The trial also looks at the safety of this treatment.

Major Depression3-6 monthsMonitoring phase (IV)6-10 visitsStandard MedicinesPsychiatry

Elderly Primary CNS Lymphoma: High-Dose Chemotherapy Study

We are comparing a high-dose chemotherapy followed by stem cell transplantation to standard chemotherapy for elderly patients with primary CNS lymphoma. The goal is to see which treatment leads to better survival and quality of life.

Primary Central Nervous System Lymphoma (PCNSL)>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesHematologyOncology

Advanced Breast Cancer: Trastuzumab Deruxtecan vs. CDK4/6 Inhibitors

We are studying whether trastuzumab deruxtecan is more effective than a combination of CDK4/6 inhibitors and endocrine therapy for patients with HR-positive, HER2-low advanced breast cancer. This research aims to improve treatment options for this specific group of patients.

Locally Recurrent or Metastatic Hormone Receptor-Positive Breast Cancer>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementEndocrinologyOncology

Small-Cell Lung Cancer: Durvalumab and Olaparib Maintenance Therapy

We are studying the effects of a combination of durvalumab and olaparib for patients with HRD-positive extensive disease small-cell lung cancer after initial treatment. The goal is to see if this maintenance therapy improves outcomes and is safe for patients.

Extensive Stage Small Cell Lung Cancer1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncologyPulmonology

Migraine Prevention in Kids: Rimegepant Study

We are testing a new medication, rimegepant, to see if it helps reduce migraine days in children and adolescents aged 6 to under 18. The study compares its effects to a placebo to understand its potential benefits.

Migraine≤3 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessStandard MedicinesPartially RemoteNeurologyPediatrics

Soft Tissue Sarcomas: INT230-6 Treatment Study

We are investigating a new treatment for adults with advanced soft tissue sarcomas to see if it works better than standard care. The study will also look at side effects and quality of life for participants.

Myxoid LiposarcomaDedifferentiated LiposarcomaRound Cell Liposarcoma>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Buprenorphine for Severe Suicidal Thoughts in Major Depression

We are studying whether buprenorphine can help reduce severe suicidal ideas in individuals with major depressive episodes. The trial will compare different doses to find the most effective and safest option.

Clinical Depression≤3 monthsEfficacy phase (II)6-10 visitsStandard MedicinesPsychiatry

Bevacizumab vs. Corticosteroids for Cerebral Radiation Necrosis

We are studying whether bevacizumab is more effective than corticosteroids for treating symptoms of cerebral radiation necrosis in patients with high-grade glioma or brain metastases. The trial also looks at quality of life and other health impacts.

Brain MetastasesHigh-Grade Glioma>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteNeurologyOncology

ANCA Vasculitis: Stopping Immunosuppressive Therapy

We are studying whether stopping immunosuppressive therapy helps patients with ANCA vasculitis and end-stage renal disease avoid serious health issues compared to continuing treatment.

End-stage Renal DiseaseANCA Vasculitis>2 yearsConfirmation phase (III)Monitoring phase (IV)11-15 visitsNo PlaceboStandard MedicinesNephrologyRheumatology

Cardiovascular Disease: Low Dose Rivaroxaban in Advanced CKD

We are studying whether a low dose of rivaroxaban can help reduce serious heart-related events in people with advanced chronic kidney disease or on dialysis. This trial compares the medication to a placebo to see if it offers any benefits.

Heart and Kidney Disease>2 yearsConfirmation phase (III)Investigational MedicinesCost ReimbursementCardiologyNephrology

Glioblastoma: Dendritic Cell Vaccine Study

We are testing a personalized vaccine made from your own immune cells and tumor tissue for patients with glioblastoma. The study aims to see if this treatment can improve safety and help patients live longer without disease progression.

Glioblastoma>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesNeurologyOncology